This endoscopic study was designed to assess histologic and functional features of human gastric mucosal injury by 40 percent ethanol, and to compare the gastroprotective effects of sucralfate with those of ranitidine or sucralfate combined with ranitidine against ethanol damage. A group of 16 young subjects with normal gastric mucosa were divided into two groups (A and B). Group A was pretreated for four days with either sucralfate alone (1 g four times per day) or placebo (one tablet four times per day). Group B received sucralfate (1 g four times per day) plus ranitidine (150 mg three times per day) or placebo plus ranitidine in a double-blind, randomized study. On the fifth morning, two hours after the last treatment, 100 ml of 40 percent ethanol spray was applied via an endoscope onto gastric mucosa. In placebo-treated subjects, ethanol caused widespread endoscopic damage (score = 2.43) with histologic disruption of surface epithelium and deep necrotic lesions accompanied by a decrease of mucosal potential difference from -41.3 to -15.8 millivolts. Pretreatment with sucralfate significantly reduced endoscopic damage (score = 0.75). The surface epithelium was disrupted, but necrotic lesions were greatly reduced and potential difference decreased to -27.1 millivolts. Ranitidine alone or combined with sucralfate did not prevent ethanol-induced histologic or functional changes in the mucosa. Ethanol produces pronounced mucosal damage that can be almost completely prevented by sucralfate.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0002-9343(89)90158-7DOI Listing

Publication Analysis

Top Keywords

times day
16
sucralfate ranitidine
8
histologic functional
8
percent ethanol
8
gastric mucosa
8
sucralfate times
8
day placebo
8
endoscopic damage
8
damage score
8
surface epithelium
8

Similar Publications

Objectives: Trauma-induced coagulopathy (TIC) can be fatal but preventable if recognised early. With emerging uses of rotational thromboelastometry (ROTEM) to guide transfusions in trauma, patient outcomes with TIC-defined by initial ROTEM and conventional coagulation tests (CCTs) during massive haemorrhage protocol (MHP) activations were evaluated at a primary trauma centre in British Columbia.

Methods: This retrospective observational study included adult trauma patients requiring MHP from June 1, 2020, to May 31, 2022.

View Article and Find Full Text PDF

Robotic-assisted costectomy using a Gigli saw for fibrous dysplasia.

J Cardiothorac Surg

January 2025

Department of Thoracic Surgery, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.

Background: Fibrous dysplasia (FD) is the most common benign tumor of the ribs, with surgical resection being the preferred treatment modality for rib FD, leading to enhanced quality of life and favorable outcomes. The complexity of surgical intervention varies depending on the location of costal FD, presenting challenges for both open surgical and thoracoscopic approaches. In this study, we present a novel technique for three-port robotic-assisted costectomy utilizing a Gigli saw, detailing our initial findings and outcomes.

View Article and Find Full Text PDF

Prolonged screen time is associated with increased severity of tic symptoms in children with tic disorders.

Ital J Pediatr

January 2025

Department of developmental and behavior pediatrics, Children's Medical Center, The First Hospital of Jilin University, Jilin University, Changchun, China.

Background: Recent studies have emphasized the association between prolonged screen exposure and neurodevelopmental disorders, though its correlation with tic disorders (TDs) remains ambiguous. We thus conducted this study to investigate the association between screen time (ST) and the severity of tic symptoms in children diagnosed with TDs.

Methods: We conducted a retrospective case-control study with 342 cases of TDs and 270 controls, collecting data from March 2021 to December 2023.

View Article and Find Full Text PDF

CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant.

Clin Lymphoma Myeloma Leuk

January 2025

Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, University of Maryland School of Medicine, Baltimore, MD.

Background: Anti-CD19 CAR-T therapy has been a breakthrough in treatment of primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant previous second line of high dose chemotherapy and autologous stem cell transplantation (HDT/ASCT). However, in clinical practice, high risk patients with chemoimmunotherapy sensitive disease continue to receive salvage chemoimmunotherapy or cannot access CAR-T in a timely manner and thus may still proceed to HDT/ASCT. Little is known about clinical outcomes of CAR-T in patients who receive HDT/ASCT compared to those who are transplant-naïve.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!